A prospective clinical multicenter study to evaluate the safety, performance and subject satisfaction when using hyaluronic acid fillers from the Mona Lisa product range by GENOSS to build facial volume and contour the face and their comparison to products from the manufacturers Across, Allergan, Galderma and Vivacy

开始日期2024-04-01

申办/合作机构

GENOSS Co., Ltd.

TCTR20240608007 / Completed临床1/2期IIT

EFFICACY OF NANOGEL FROM GRAFTED HYALURONIC ACID SALIVA SUBSTITUTES IN THE TREATMENT OF DRY MOUTH

开始日期2023-12-22

申办/合作机构-

NCT03561779 / Completed临床3期

A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Study to Evaluated the Safety and Efficacy of Intraarticular Hyalurinic Acid(YYD302) for Osteoarthritis of the Knee After 12 Weeks of Treatment and Retreatment

This is a randomized, double-blind, active-controlled, multi-center, phase 3 study to evaluate the safety and efficacy of intraarticular hyaluronic acid(YYD302) for osteoarthritis of the knee after 12 weeks of treatment and retreatment

开始日期2018-02-21

申办/合作机构

Yooyoung Pharm Co. Ltd.

100 项与 YY-1201 相关的临床结果

登录后查看更多信息

100 项与 YY-1201 相关的转化医学

登录后查看更多信息

100 项与 YY-1201 相关的专利（医药）

登录后查看更多信息

项与 YY-1201 相关的文献（医药）

2024-07-01·Gynecology and Minimally Invasive Therapy

Pregnancy in Infertile Patient after Intrauterine Adhesiolysis by Multitherapeutic Strategy: A Case Report and Mini-review

Article

作者: Dinh, Hoang The ; Tran, An Nguyen Phuong ; Nguyen, Nhan Trong

AbstractAsherman’s syndrome, characterized by intrauterine adhesions (IUAs), represents a significant challenge in the field of female infertility. Hysteroscopic adhesiolysis has emerged as the gold standard for both the diagnosis and treatment of Asherman’s syndrome. Understanding the intricate relationship between Asherman’s syndrome, uterine adhesiolysis, and infertility is crucial for guiding comprehensive and effective management strategies. The success of the treatment is contingent upon preventing adhesion recurrence, particularly in cases of severe IUAs. This is the first case, in which we employed a multifaceted preventive approach, utilizing hyaluronic gel, Foley balloon, hormonal therapy, and platelet-rich plasma, achieving successful pregnancy following embryo transfer despite the presence of severe IUAs. The patient, a 35-year-old female, underwent one cesarean section following in vitro fertilization and required dilation and curettage due to retained products of conception. The patient presented with oligohemorrhage, and the uterine lining was thin while using hormones for endometrial preparation. The diagnosis of severe IUAs was confirmed through ultrasound and hysteroscopic examination of the uterine cavity. The patient underwent hysteroscopic adhesiolysis with a preventive approach using a combination of methods. Subsequently, the patient underwent a second-look hysteroscopy to assess the uterine cavity and achieved successful embryo transfer. The patient carried the pregnancy to 38 weeks and underwent repeated cesarean section due to the vertex-vertex presentation of the twins.

2023-10-01·Rehabilitación

Análisis de periodicidad de reinyección en gonartrosis con distintos tipos de ácidos hialurónicos

Letter

作者: Fernández-Cuadros, M E ; Albaladejo-Florín, M J

2023-01-01·GMS Interdisciplinary plastic and reconstructive surgery DGPW

Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia^® Complexion Analysis camera system for objective skin analysis.

Article

作者: Henseler, Helga

ObjectiveTo analyze the effects of Argireline on skin surface wrinkles using the Visia^® camera system developed by Canfield Scientific Inc., U.S.A., for facial image capture.MethodNineteen female participants were recruited from a plastic surgery clinic. Initial facial images captured the left, front, and right sides of the participants' faces, which were documented as timepoint one. Following this, the participants immediately began to apply a facial skin serum containing triple hyaluronic acids produced by CNC cosmetic GmbH, Philippsburg, Germany. The serum was applied once in the morning and once in the evening. Participants received two identical containers labeled L for left and R for right, with each container to be used on the corresponding facial side, particularly around the eye area. One container contained Argireline, a synthetic hexapeptide, which previously was deemed to be a biosafe alternative to botulinum neurotoxin. The study was conducted as double-blind; neither the participants nor researchers knew which of the two containers contained Argireline. Participants were allowed to use their own cosmetic products throughout the study. After four weeks, the participants returned to have their faces recaptured using the Visia^® camera, which was documented as timepoint two. The absolute scores of the wrinkles were noted, and results on both sides of the face were calculated and compared. The "TruSkinAge^®" measurement provided by the Visia^® camera was reviewed for each face side. Results between both time points and both sides of the face were compared. After the data analysis was complete, the company was contacted to determine which container contained Argireline.ResultsNineteen participants returned for facial image capture. There were no significant adverse events, allergic reactions, or skin irritations. The investigation revealed that the wrinkle score slightly decreased for the right and left side of the face following four weeks of serum application. However, this decrease was not significant (p>0.05) based on the Wilcoxon matched pairs tests for the wrinkle scores (right side p=0.060 and left side p=0.176) and Truskin Ages^® results (right side p=0.096 and left side p=0.489).Comparing the data from the right side with that from the left side of the face revealed that neither demonstrated a significant reduction in wrinkle score (p=0.829) or Truskin Ages^® results (p=0.804). Argireline was included in the serum applied to the right side of the face. However, no statistical significance was seen in the results on this side of the face indicating any possible effects.ConclusionWrinkle scores and Truskin Ages^® results were observed to decrease non-significantly following the application of a skin serum involving hyaluronic acid. The Visia^® imaging method was used to analyze the data objectively. Differences between both sides of the face that were treated with and without Argireline were not statistically significant. Therefore, the effect of Argireline was not proven. While Argireline presented with low toxicity, its efficacy was found not to be significant. Therefore, it is not deemed to be an alternative treatment to botulinum toxin.

项与 YY-1201 相关的新闻（医药）

2023-01-03

·BioSpace

Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023

Encinitas, California--(News - January 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced enrollment has been completed in its clinical study evaluating KIO-201 in patients with Persistent Corneal Epithelial Defects ("PCED"), a rare ocular condition characterized by non-healing wounds on the surface of the eye. Results from the study are expected to be reported at an upcoming medical conference in the first half of 2023. "This study is an important step to tackle some of the most challenging and difficult-to-treat corneal wounds," said Eric Daniels, M.D., Chief Development Officer of Kiora Pharmaceuticals. "Current standard of care for these patients is sub-optimal with respect to outcomes and remains a substantial burden for patients. We believe KIO-201, an eye drop that is easily administered at home, addresses many of these challenges. As part of our development strategy of addressing unmet and orphan ophthalmic diseases, we have applied for Orphan Drug Designation of KIO-201 for PCED. Further, based on initial observations, we have started planning discussions with the FDA for a Phase 3 registration study of KIO-201 in PCED." PCEDs are characterized by an inability of the cornea to properly repair the protective epithelial surface of the eye. This can be due to a variety of underlying factors including physical trauma, surgical injury, infections, or inflammatory ocular diseases. When corneas are unable to heal, patients' eyes are susceptible to recuring infections, debilitating pain, scarring and reduced vision. It is estimated that there are fewer than 200,000 patients diagnosed annually in the United States with PCED[1]. The trial was designed as a single-arm, open label ten patient (up to 20 eyes) study. Patients were evaluated at various timepoints up to 28 days after receiving KIO-201 six times daily. The endpoints included safety and tolerability︎, as well as the percentage of patients achieving corneal healing and the associated time to complete corneal healing as determined by corneal fluorescein staining. KIO-201 is a chemically-modified, cross-linked form of the natural polymer Hyaluronic Acid (HA). HAs are involved in natural corneal wound healing but are thought to be limited by shortened ocular resonance time. Formulated as a convenient topical eye drop, KIO-201 provides a thin coating to the surface of the eye and serves as a protectant to facilitate and accelerate corneal re-epithelization. The chemical modifications enable enhanced viscoelastic properties and lengthen the ocular surface resonance time compared to standard hyaluronic acids. About Kiora Pharmaceuticals Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid Arthritis ("OPRA"). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase ("DHODH") with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing. In addition to news releases and SEC filings, we expect to post information on our website, , and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts. Forward-Looking Statements Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, results from this study that could support Kiora's efforts to advance KIO-201 to more advanced stages of clinical development, the expected timing of results from the study, the ability of KIO-201 to address challenges with the treatment of corneal wounds, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Amendment No. 1 to Annual Report on Form 10-K/A filed with the SEC on July 7, 2022 or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law. Investor Contact Francina Agosti, PhD (617) 546-0742 fagosti@reportablenews.com [1] Vaidyanathan U, Hopping GC, Liu HY, et al. Persistent Corneal Epithelial Defects: A Review Article. Med Hypothesis Discov Innov Ophthalmol. 2019;8(3):163-176. To view the source version of this press release, please visit

孤儿药

2022-07-27

·BioSpace

Americas Hospital Acquired Infection Testing Industry Analysis Predicts The Market To Attain A Valuation Of US$ 2.7 Bn By The End Of The Decade; States Fact.MR

“Surge in surgical procedures and government initiatives to control & create awareness regarding hospital acquired infections are anticipated to drive market growth over the coming years,” says a Fact.MR analyst. Americas Hospital Acquired Infection Testing Market Analysis By Test (MSRA, Clostridium difficile Testing Kits), By Modality (Immunoassay Testing, Point-of-care Testing), By Sample (Blood, Nasal Swabs, Urine, Stool), By End User, By Region - Global Insights 2021-2031 Fact.MR - A Market Research And Competitive Intelligence Provider, the Americas hospital acquired infection testing market was valued at US$ 595 Million in 2020, and is expected to exhibit a CAGR of around 15% over the forecast period (2021-2031). Rise in surgical procedures are elevating the risk of contracting surgical site infections. Surgical site infections (SSIs) are the most commonly reported healthcare-acquired infections and surgical complication in both, developed and developing countries. Infants, elderly people, and people with weak immunity systems are at a greater risk of developing hospital acquired infections (HAIs). Many common antibiotics are resistant to various organisms present in hospitals. Widespread use of antibiotics in hospitals promotes the development of resistant bacteria. Urinary tract infection (UTI), surgical site infections, pneumonia, lung infections, and bacterial infections are commonly acquired hospital infections. For More Insights on this Market, Get A Sample Report! As per the Centers of Disease Control and Prevention (CDC) estimates, in hospitals across the Americas alone, 1.7 million patients suffer from HAIs and 99,000 deaths occur every. This high mortality rate associated economic burden has compelled healthcare providers to device an effective strategy to lower infection rates. There are various barriers that service providers have to face while introducing new tests or kits in the market. One amongst these is stringent government regulations. Diagnostic kits that are developed by independent medical device manufacturers and sold to medical laboratories are subjected to strict regulatory guidelines and a lengthy FDA approval process. Key Takeaways from Market Study By test, helicobacter pylori testing kits hold around 26.4% value share of the total Americas market. Based on modality, point-of-care testing is leading with 69% market share. By end user, diagnostic laboratories dominate the HAI testing market with a value share of 35%, while on the other hand, home care settings are expected to increase at a higher CAGR of 23%. By country, the U.S. dominates the Americas hospital acquired infection testing market with a value share of 58%. To Gain In-Depth Insights on Americas Hospital Acquired Infection Testing Market, Request Methodology at Competitive Landscape - The Americas market is set to expand due to rise in incidence of hospital acquired infections. Leading industry players are set to focus on research & development as well as strategic & geographic expansion in order to strengthen their presence in the region. Some of the leading players in the market include, but not limited to, Altona Diagnostics, bioMérieux SA, Abbott, ThermoFisher Scientific, Danaher Corporation, ELI Tech Group, Becton Dickinson, Hoffmann-La Roche Ltd, Qiagen, Pro-lab diagnostics, Liofilchem, savyonDiagnostics, and CTK Biotech. Impact of COVID-19 on Hospital Acquired Infection Testing in the Americas – The current COVID-19 pandemic crisis is expected to have a moderately positive impact on market growth. This can be attributed to growing number hospitalizations due to COVID-19 across the Americas. Prolonged hospital stays and frequent use of ventilators increase the chances of patients acquiring infections. Thus, as the number of hospitalizations is high, demand for HAI testing kits is expected to see a rise. Segments as per Americas Hospital Acquired Infection Testing Industry Research By Test MSRA Testing Kits MRSA Real-Time PCR Detection Kits MRSA Rapid Test Kits Staphylococcus aureus Detection Kits Staphylococcus aureus Latex Test Kits Staphylococcus aureus Assay Test Kits Clostridium difficile Testing Kits Clostridium difficile Detection Panels Clostridium difficile Immunoassay Kits Helicobacter pylori Testing Kits Helicobacter pylori Rapid Antigen Test Kits Helicobacter pylori IgG antibodies Test Kits Rotavirus/ Adenovirus Real-time PCR Kits RSV RT-PCR Test Kit RSV Ag Rapid Test Kits Strep A Rapid Testing Kits Strep B Rapid Testing Kits Mononucleosis Testing Kits Calprotectin Test Kits Modality Immunoassay Testing Point-of-care Testing By Sample Blood Nasal Swabs Urine Stool By End User Hospitals Diagnostic Laboratories Cancer Research Institutes Specialty Clinics Home Care Settings Interested to Procure The Data? Inquire here Want more insights? Fact.MR brings a comprehensive research report on forecasted revenue growth at the Americas, regional, and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The Americas hospital acquired infection testing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the basis of test, modality, sample, and end user, across three main regions. Fact.MR’s Domain Knowledge on Healthcare Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support - encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions. Explore Fact.MR’s Coverage on the Healthcare Domain Anti-snoring Devices and Snoring Surgery Market - Anti-snoring Devices and Snoring Surgery Market By Device (Mandibular Advancement, Tongue Stabilizing, Continuous Positive Airway Pressure (CPAP)), By Surgical Procedure (Uvulopalatopharyngoplasty, Tonsillectomy and Adenoidectomy) - Regional Forecast 2021-2031 Antacids Market - Antacids Market Analysis Report By Drug Class (Proton Pump Inhibitors, H2 Antagonists), By Distribution Channel (Hospital, Retain Pharmacies), By Formulation, By Region - Global Market Insights 2020-2025 Antimicrobial Susceptibility Test Market - Antimicrobial Susceptibility Test Market Analysis Repot By Product (Kits, Reagents, & Consumables, Automated Test Systems, Culture Media), By Application (Clinical Diagnosis, Drug Discovery and Development), By End User, By Region - Global Insights 2020-2025 Anti-aging and Anti-wrinkle Products Market - Anti-aging and Anti-wrinkle Products Market Analysis Repot By Product (Serum, Creams, Gels), By Treatment (Body, Facial Care Treatment), By Ingredient (Retinoid, Hyaluronic Acids, Alpha-Hydroxy Acids), By Region - Global Insights 2020-2027 Anticoagulant Reversal Drugs Market - Anticoagulant Reversal Drugs Market Analysis Repot By Product (Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, Andexxa), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region - Global Insights 2020-2026 Anticancer Drugs Market - Anticancer Drugs Market Analysis Repot By Drug Type (Targeted Drugs, Cytotoxic Drugs, Hormonal Drugs), By Cancer Type (Lung Cancer, Breast Cancer, Leukemia, Colorectal Cancer), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy) - Global Market Forecast 2020-2025 Apheresis Market - Apheresis Market Analysis Repot By Technology (Centrifugation, Membrane Filtration), By Product (Devices, Disposables), By Application (Renal Diseases, Neurology, Haematology, Cancer, Autoimmune Diseases,Cardiovascular Diseases), By Region - Global Market Forecast 2020-2025 Aptamers Market - Aptamers Market Analysis Repot By Application (Research, Diagnostics, Therapeutics), By Selection Technique (SELEX Technique), By Material (Nucleic Acid Aptamers, Peptide Aptamers), By Region - Global Market Forecast to 2010-2025 Behavioural Health Treatment Market - Behavioural Health Treatment Market Analysis Report By Disorder (Depression, Anxiety, Schizophrenia, Bipolar Disorder, Alcohol Use Disorders, Substance Use Disorders, Eating Disorders, Post-traumatic Stress Disorders), By Service, By Region -Global Forecast 2020-2027 Assisted Reproductive Technology Market - Assisted Reproductive Technology Market Analysis Report By Procedure (Frozen Donor, Frozen Non-donor, Fresh Donor, Fresh Non-donor, Embryo Banking), By Technology (In-vitro Fertilization, Surrogacy, Artificial Insemination), By End User(Fertility Clinics, Hospitals, Other )- Global Market Insights to 2019-2025 About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. 80% of Fortune 1000's trusts us in critical decision making. We provide both qualitative and quantitative research, spanning market forecast, market segmentation, competitor analysis, and consumer sentiment analysis. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Follow Us: LinkedIn | Twitter

抗体免疫疗法

100 项与 YY-1201 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB08818

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床3期	韩国	Yooyoung Pharm Co. Ltd.	2018-02-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03561779 (Pubmed \| Med Lett Drugs Ther)	临床3期	膝关节炎	184	YYD302	糧憲壓遞壓選憲壓構簾(膚衊齋窪獵壓鹹願壓簾) = 觸獵淵獵觸餘鑰鏇構醖餘膚構範製糧衊鑰鏇衊 (淵範觸構構築鏇蓋衊艱 )	积极	2021-11-01
				Synovian	糧憲壓遞壓選憲壓構簾(膚衊齋窪獵壓鹹願壓簾) = 顧夢範醖壓膚膚憲製蓋餘膚構範製糧衊鑰鏇衊 (淵範觸構構築鏇蓋衊艱 )